SEATTLE, May 19, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced that data highlighting pacritinib, including additional safety and long-term follow up data from the Phase 3 PERSIST-1 clinical trial, will be presented at the upcoming American Society...